成殷;崔全才;

• 1:中国医学科学院 北京协和医学院 北京协和医院病理科

摘要(Abstract)：

<正>甲状腺滤泡癌(follicular thyroid carcinoma,FTC)发病率在甲状腺恶性肿瘤中排位第2,约占甲状腺恶性肿瘤的10%~15%,通常经血行转移至肺、骨等部位,部分患者在肿瘤转移或复发后才被确诊。FTC常以临床病理血管、包膜浸润为诊断依据,但有时因未见明确的浸润灶或因取材不足而漏诊,为此对FTC的认识尚有待提高。

关键词(KeyWords)： 甲状腺滤泡癌;研究进展

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 成殷;崔全才;

Email:

DOI:

参考文献(References)：

• [1]LiVolsi VA,Baloch ZW.Follicular neoplasms of the thyroid:view,biases,and experiences[J].Adv Anat Pathol,2004,11:279-287.
• [2]Williams D.Cancer after nuclear fallout:lessons from the Chernobyl accident[J].Nat Rev Cancer,2002,2:543-549.
• [3]DeLellis RA,LIoyd RV,Heitz PU,et al.World Health Organization classification of tumours:pathology and genetics of tumours of endocrine organs[M].Lyon:IARC press,2004.
• [4]Vitagliano D,Portella G,Troncone G,et al.Thyroid targeting of the N-ras(Gln61Lys)oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas[J].Oncogene,2006,25:5467-5474.
• [5]Suzuki H,Willingham MC,Cheng SY.Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma:a mouse model of thyroid carcinogenesis[J].Thyroid,2002,12:963-969.
• [6]Lu C,Zhu X,Willingham MC,et al.Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma[J].Oncogene,2012,31:2007-2016.
• [7]Reddi HV,McIver B,Grebe SK,et al.The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis[J].Endocrinology,2007,148:932-935.
• [8]Nikiforova MN,Lynch RA,Biddinger PW,et al.RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors:evidence for distinct molecular pathways in thyroid follicular carcinoma[J].J Clin Endocrinol Metab,2003,88:2318-2326.
• [9]Bhaijee F,Nikiforov YE.Molecular analysis of thyroid tumors[J].Endocr Pathol,2011,22:126-133.
• [10]Kalvakolanu DV.The GRIMs:a new interface between cell death regulation and interferon/retinoid induced growth suppression[J].Cytokine Growth Factor Rev,2004,15:169-194.
• [11]Nagy R,Ganapathi S,Comeras I,et al.Frequency of germline PTEN mutations in differentiated thyroid cancer[J].Thyroid,2011,21:505-510.
• [12]Hou P,Ji M,Xing M.Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors[J].Cancer,2008,113:2440-2447.
• [13]Vella V,Puppin C,Damante G,et al.DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells[J].Int J Cancer,2009,124:2539-2548.
• [14]Yeager N,Klein-Szanto A,Kimura S,et al.Pten loss in the mouse thyroid causes goiter and follicular adenomas:insights into thyroid function and cowden disease pathogenesis[J].Cancer Res,2007,67:959-966.
• [15]Antico-Arciuch VG,Dima M,Liao XH,et al.Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females[J].Oncogene,2010,29:5678-5686.
• [16]Miller KA,Yeager N,Baker K,et al.Oncogenic K-ras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo[J].Cancer Res,2009,69:3689-3694.
• [17]Liu Z,Hou P,Ji M,et al.Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers[J].J Clin Endocrinol Metab,2008,93:3106-3116.
• [18]Saji M,Narahara K,McCarty SK,et al.Akt1 deficiency delays tumor progression,vascular invasion,and distant metastasis in a murine model of thyroid cancer[J].Oncogene,2011,30:4307-4315.
• [19]Williams ED.Guest editorial:two proposals regarding the terminology of thyroid tumors[J].Int J Surg Pathol,2000,8:181-183.
• [20]Liu Z,Zhou G,Nakamura M,et al.Encapsulated follicular thyroid tumor with equivocal nuclear changes,so-called welldifferentiated tumor of uncertain malignant potential:a morphological,immunohistochemical,and molecular appraisal[J].Cancer Sci,2011,102:288-294.
• [21]Smith RA,Salajegheh A,Weinstein S,et al,Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant[J].Hum Pathol,2011,42:500-506.
• [22]Rivera M,Ricarte-Filho J,Knauf J,et al,Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes(encapsulated vs infiltrative)reveals distinct BRAF and RAS mutation patterns[J].Mod Pathol,2010,23:1191-1200.
• [23]Pusztaszeri M,Pache JC,Karenovics W,et al,A non-invasive encapsulated macrofollicular variant of papillary thyroid carcinoma presenting with gross lymph node metastasis:a case report and literature review[J].Thyroid,2013,23:1178-1179.
• [24]Rivera M,Ricarte-Filho J,Patel S,et al.Encapsulated thyroid tumors of follicular cell origin with high grade features(high mitotic rate/tumor necrosis):a clinicopathologic and molecular study[J].Hum Pathol,2010,41:172-180.
• [25]Volante M,Collini P,Nikiforov YE,et al.Poorly differentiated thyroid carcinoma:the turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach[J].Am J Surg Pathol,2007,31:1256-1264.
• [26]van Heerden JA,Hay ID,Goellner JR,et al.Follicular thyroid carcinoma with capsular invasion alone:a nonthreatening malignancy[J].Surgery,1992,112:1130-1136;discussion 1136-1138.
• [27]Lang W,Choritz H,Hundeshagen H.Risk factors in follicular thyroid carcinomas.A retrospective follow-up study covering a 14-year period with emphasis on morphological findings[J].Am J Surg Pathol,1986,10:246-255.
• [28]Magro G,Cataldo I,Amico P,et al.Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target[J].Thyroid,2011,21:267-277.
• [29]Abulkheir IL,Mohammad DB.Value of immunohistochemical expression of p27 and galectin-3 in differentiation between follicular adenoma and follicular carcinoma[J].Appl Immunohistochem Mol Morphol,2012,20:131-140.
• [30]HeikkilA,Hagstrm J,MenpH,et al.Loss of estrogen receptor Beta expression in follicular thyroid carcinoma predicts poor outcome[J].Thyroid,2013,23:456-465.
• [31]Sugino K,Kameyama K,Ito K,et al.Outcomes and prognostic factors of 251 patients with minimally invasive follicular thyroid carcinoma[J].Thyroid,2012,22:798-804.
• [32]Kangelaris GT,Orloff LA.Prognostic factors for minimally invasive follicular thyroid carcinoma[J].Laryngoscope,2011,121:S130.